Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Novartis Korea Venture Fund, OrbiMed's Caduceus Asia Partners and local vaccine producer Green Cross plan to invest $6 million in the next three years to support development of PharmAbcine's fully human monoclonal antibodies to treat cancer and inflammatory diseases

You may also be interested in...



Novartis Venture Fund Supporting Korea's Bio Start-ups

Series B financing for the fund's first investment is seen by Novartis as validation for discovery efforts.

Korean Biotechs Battle For Funding and Attention Underneath Chinese Shadow

SEOUL - Korean biotechs are producing siginificant R&D output, but there is a disconnect between local companies' scientific and financial success, and the country needs to utilize new models to build a viable biotech industry, according to panelists at Bio Korea 2010

Korean Biotechs Battle For Funding and Attention Underneath Chinese Shadow

SEOUL - Korean biotechs are producing siginificant R&D output, but there is a disconnect between local companies' scientific and financial success, and the country needs to utilize new models to build a viable biotech industry, according to panelists at Bio Korea 2010

Related Content

UsernamePublicRestriction

Register

LL1133273

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel